Jump to ContentJump to Main Navigation

Online

249,00 € / $374.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
January 2010
ISSN:
1437-4331
DOI:
10.1515/cclm.2010.011

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 249.00
RRP for USA, Canada, Mexico
US$ 374.00 *
Print
Individual Subscription Online only
Euro [D] 1577.00
RRP for USA, Canada, Mexico
US$ 2365.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1893.00
RRP for USA, Canada, Mexico
US$ 2838.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the International Federation of Clinical Chemistry and Laboratory Medicine and the European Federation of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Lippi, Giuseppe / Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Melichar, Bohuslav / Siest, Gérard / Whitfield, John B. / Abi Fadel, Marianne / Alvarez Menendez, Francisco V. / Azzazy, Hassan M.E. / Diamandis, Eleftherios P. / Eckardstein, Arnold / Favaloro, Emmanuel J. / Griesmacher, Andrea / Herrmann, Wolfgang / Hoffmann, Johannes J.M.L. / Hooijkaas, Herbert / Ichihara, Kiyoshi / Kaabachi, Naziha / Kim, Jeong-Ho / Korte, Wolfgang / Kroupis, Christos / Lai, Leslie Charles / Lam, Wai Kei Christopher / Marc, Janja / Miyoshi, Eiji / Özben, Tomris / Palicka, Vladimir / Panteghini, Mauro / Queralto, Jose M. / Scartezini, Marileia / Simundic, Ana-Maria / Tsongalis, Gregory J. / Wallemacq, Pierre E. / Yan, Shengkai / Young, Ian S. / Chiu, Rossa Wai Kwun / Ghosh, Debabrata / Kappelmayer, Janos / Lehmann, Sylvain / Sypniewska, Grazyna

12 Issues per year

Increased IMPACT FACTOR 2011: 2.150
Rank 10 out of 32 in category Medical Laboratory Technology in the 2011 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Improvement of the cardiac marker N-terminal-pro brain natriuretic peptide through adjustment for renal function: a stratified multicenter trial

Andreas Luchner1 / Alexander Weidemann2 / Roland Willenbrock3 / Sebastian Philipp4 / Norbert Heinicke1 / Matthias Rambausek5 / Uta Mehdorn6 / Burkhard Frankenberger7 / Iris M. Heid8 / Kai-Uwe Eckardt2 / Stephan R. Holmer1

1Klinik und Poliklinik für Innere Medizin II, Klinikum der Universität Regensburg, Regensburg, Germany

2Medizinische Klinik 4 mit Schwerpunkt Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Erlangen, Germany

3Medizinische Klinik, St. Elisabeth Krankenhaus, Halle/Saale, Germany

4Klinik für Kardiologie, Westdeutsches Herzzentrum der Universität Duisburg-Essen, Essen, Germany

5Dialysezentrum Heilbronn, Heilbronn, Germany

6Dr. Köhler GmbH, Freiburg, Germany

7Gesellschaft zur Durchführung klinischer Studien – GDS mbH, Wuppertal, Germany

8Institut für Epidemiologie, Universitaet Regensburg, Regensburg, Germany

Corresponding author: Prof. Dr. Andreas Luchner, FESC, Klinik und Poliklinik für Innere Medizin II – Kardiologie, Klinikum der Universität, 93042 Regensburg, Germany Phone: +49 941 944-7211, Fax: +49 941 944-7213,

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Issue 1, Pages 121–128, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm.2010.011, January 2010

Publication History:
Received:
2009-03-03
Accepted:
2009-09-05
Published Online:
2010-01-05

Abstract

Background: N-terminal-pro brain natriuretic peptide (NT-proBNP) is a useful cardiac marker that is also influenced by renal dysfunction. It was our objective to assess the relationship between NT-proBNP concentrations in plasma and worsening renal function, and to attempt adjustment of NT-proBNP for renal dysfunction in a prospective, stratified multi-center study.

Methods: We stratified 203 male patients according to their cardiac status and the estimated glomerular filtration rate (eGFR). Cardiac disease was assessed by medical history, physical examination and standardized echocardiography. Patients were stratified according to the following: absence of cardiac history and abnormalities (control, CTRL, n=66), cardiac history without left ventricular hypertrophy (LVH) or left ventricular systolic dysfunction (LVD) (history, n=30), LVH without systolic dysfunction (LVH, n=68), and LVD [ejection fraction (EF) <40%, LVD, n=39]. Renal disease was stratified according to the eGFR: 15–30 mL/min (n=52), 31–75 mL/min (n=99), and >75 mL/min (n=52).

Results: NT-proBNP was correlated with eGFR in the entire study population and for all levels of cardiac disease (all p<0.01). Regression analysis allowed adjustment of NT-proBNP for eGFR in a continuous manner, and this adjustment significantly improved the predictive value (receiver operating characteristic curve for symptomatic LVD from 0.80 to 0.86, p<0.01; sensitivity from 74% to 83% and specificity from 68% to 79%).

Conclusions: NT-proBNP correlates inversely and significantly with eGFR throughout all levels of cardiac strata. We propose for the first time a continuous adjustment algorithm which markedly improves the predictive values of NT-proBNP in male patients with impaired renal function.

Clin Chem Lab Med 2010;48:121–8.

Keywords: echocardiography; glomerular filtration; heart; kidney; natriuretic peptide

Comments (0)

Please log in or register to comment.